EMBC

$8.91

Post-MarketAs of Mar 17, 8:00 PM UTC

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$8.91
Potential Upside
376.8%
Whystock Fair Value$42.48
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Instruments & Supplies

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection device...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$527.65M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
3.78
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.06
Div Yield
Strong income play. Yield provides a meaningful total return floor.
680.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.54

Recent News

Simply Wall St.
Feb 12, 2026

We Think Embecta's (NASDAQ:EMBC) Solid Earnings Are Understated

Despite posting healthy earnings, Embecta Corp.'s ( NASDAQ:EMBC ) stock has been quite weak. Our analysis suggests that...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Feb 11, 2026

Embecta (NASDAQ:EMBC) Is Paying Out A Dividend Of $0.15

The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 17th of...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Feb 6, 2026

3 Healthcare Stocks Paying the Highest Dividends of 2026

Which of the highest-yielding healthcare stocks are value traps or golden opportunities?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 5, 2026

Embecta Q1 Earnings Call Highlights

Embecta (NASDAQ:EMBC) said it is transitioning from a “stand-up” phase of independence to a “seed growth” phase as management works to stabilize its core insulin delivery franchise, expand the portfolio, and build financial flexibility. On the company’s fiscal first-quarter 2026 earnings call, execu

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 5, 2026

Embecta Corp (EMBC) Q1 2026 Earnings Call Highlights: Strategic Progress Amidst Market Challenges

Embecta Corp (EMBC) showcases strong international growth and strategic advancements in GLP-1 collaborations, despite facing pricing pressures in the US market.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.